Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials

Adalimumab Medium‐Term Dosing Strategy in Moderate‐to‐Severe Hidradenitis Suppurativa: Integrated Results from the Phase 3, Randomized, Placebo‐Controlled, PIONEER Trials

(2019) G.B.E. Jemec et al.   BRITISH JOURNAL OF DERMATOLOGY

Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa

(2018) J.R. Ingram et al.   BRITISH JOURNAL OF DERMATOLOGY

Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A.

(2018) A. Garg et al.   BRITISH JOURNAL OF DERMATOLOGY

A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process

(2018) L. Thorlacius et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

(2018) Christos C. Zouboulis et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Hurley III Hidradenitis Suppurativa Has an Aggressive Disease Course

(2018) Annika M.J.D. Vanlaerhoven et al.   DERMATOLOGY

Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States

(2017) Amit Garg et al.   JAMA Dermatology

The Genetics of Hidradenitis Suppurativa

(2016) John R. Ingram   DERMATOLOGIC CLINICS

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

(2016) Alexa B. Kimball et al.   NEW ENGLAND JOURNAL OF MEDICINE

Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data

(2015) M.K.A. Basra et al.   DERMATOLOGY

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study

(2015) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment

(2014) A.B. Kimball et al.   BRITISH JOURNAL OF DERMATOLOGY

The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppurativa

(2013) G.R. Vinding et al.   BRITISH JOURNAL OF DERMATOLOGY

Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments

(2012) Hessel H. van der Zee et al.   EXPERIMENTAL DERMATOLOGY

Hidradenitis Suppurativa

(2010) F. William Danby et al.   DERMATOLOGIC CLINICS